(HumanPAX7demonstrates a slightly higher sequence identity withDrosophilaPAX3/7than does humanPAX3 and is used here.) We founddRASSFmRNA overexpressed 2.6-fold in PAX7-FOXO1 larval muscle (ArrayExpress database accession number E-MTAB-839), suggesting that similarly to the human myoblast model, thisDrosophila model of aRMS shows upregulated RASSF. We next examined whether dRASSF promotes PAX-FOXO1 phenotypes by screening the effect ofDrosophilamutants that alterdRASSFlevels or function. signaling, was upregulated in RMS tumors. These data suggest that Hippo pathway dysfunction promotes RMS. This work provides evidence for Hippo pathway suppression in aRMS and demonstrates a Edonerpic maleate progrowth role for RASSF4. Additionally, we identify a mechanism used by PAX3-FOXO1 to inhibit MST1 signaling and promote tumorigenesis in aRMS. == Introduction == Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of child years and adolescence. Over the past 30 years, clinical trials in North America, Europe, Edonerpic maleate and Australia have identified superior treatment strategies leading to the improved survival of discrete groups of RMS patients. A distinctly worse end result is usually encountered for patients with the alveolar histologic variant of RMS (aRMS), who have a 5-12 months survival rate of less than 50% (1). Even more dismal is the survival for those whose tumors express the signature paired box 3-forkhead box protein O1 (PAX3-FOXO1) fusion gene; in the metastatic setting, their survival rate at 4 years is usually less than 10% (2). Although PAX3-FOXO1 (and the related fusion protein PAX7-FOXO1) was recognized in the 1990s (35) and intensely analyzed in terms of its regulation, downstream targets, and cellular phenotypic effects, a unified understanding of how the fusion gene and its resulting oncoprotein contribute so profoundly to aRMS tumorigenesis remains obscure. To understand the discrete molecular actions involved in aRMS tumorigenesis, we constructed a genetically defined model of aRMS based on the sequential introduction of a defined set of oncogenic cDNAs (PAX3-FOXO1,hTERT,MycN) into primaryhumanskeletalmusclemyoblasts (HSMMs). When implanted in immunodeficient mice, these transformed cells (abbreviated herein as HSMMPF+H+M) produce xenografts whose morphology and histologic markers mimic aRMS (6). The order of expression of the cDNAs is usually important for faithful generation of the model; most critically,PAX3-FOXO1must be launched first for the cells to transform in vivo. This suggests that PAX3-FOXO1 imparts crucial cellular changes (genetic or epigenetic) that support subsequent tumorigenic steps and that investigation of these changes will provide needed insight into aRMS tumorigenesis. One such crucial change required for tumorigenicity of main HSMMs stably expressing PAX3-FOXO1 is usually proliferation past the senescence checkpoint (7). This observation suggests that PAX3-FOXO1 permits continued cell growth in an ordinarily prohibitive environment. The Hippo signaling pathway is usually a highly conserved tumor suppressor cascade best known for its role in regulating organ Edonerpic maleate size. The core components of the Hippo pathway are the MST1/2 and LATS1/2 tumor suppressor kinases, the RASSF, SAV1, and MOB1 adaptor proteins, the YAP transcriptional regulator, and the TEAD transcription factors. MST/RASSF, MST/SAV1, and LATS/MOB1 signaling complexes coordinate a tumor-suppressive signaling cascade that inhibits the nuclear localization and activation of YAP. YAP, when in the nucleus, regulates activation of the TEAD transcription factors, promoting the expression of pro-proliferative and survival genes (8). During normal growth and development, the Hippo pathway provides tumor suppressor functions at the intersection of cell proliferation, differentiation, and apoptosis. Not surprisingly, malignancies have developed to corrupt this pathway. MST/LATS loss or YAP overexpression lead to tumorigenesis in mouse models (914), demonstrating that Edonerpic maleate Hippo pathway inhibition is sufficient for tumorigenesis. Identifying the mechanisms of Hippo pathway inactivation in human cancer will be paramount in finding ways to exploit this pathway therapeutically. In the current work, we have examined the transcriptional changes regulated by PAX3-FOXO1 in main HSMMs and identifiedRASSF4as a novel PAX3-FOXO1 transcriptional target. We foundRASSF4highly expressed in PAX3-FOXO1positive aRMS and its expression necessary for aRMS cell proliferation, senescence evasion, and tumorigenesis. Mechanistically, we show that RASSF4 associates with MST1 kinase to inhibit downstream signaling in PAX3-FOXO1positive aRMS. We also show that YAP is usually upregulated in both major RMS subtypes, suggesting that Hippo pathway dysregulation is an essential element of RMS tumorigenesis. == Results == == PAX3-FOXO1 promotes transcriptional changes in Edonerpic maleate main human myoblasts. == We have shown previously that this expression of exogenousPAX3-FOXO1in combination with p16INK4Aloss in main HSMMs is required for the generation of a genetic model of aRMS (6).PAX3-FOXO1expression in these Rabbit polyclonal to PPP1CB main cells promotes senescence bypass, priming cells for transformation and tumor formation. Since the PAX3-FOXO1 protein is considered a hyperactive transcription factor (15),.